Kevin McManus - Syndax Pharmaceuticals Chief Officer
| SNDX Stock | USD 23.18 0.68 3.02% |
Executive
Kevin McManus is Chief Officer of Syndax Pharmaceuticals
| Age | 55 |
| Phone | 781 419 1400 |
| Web | https://www.syndax.com |
Syndax Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of (0.2589) % which means that it has lost $0.2589 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.4099) %, meaning that it created substantial loss on money invested by shareholders. Syndax Pharmaceuticals' management efficiency ratios could be used to measure how well Syndax Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Susan Fischer | Aerovate Therapeutics | N/A | |
| John Jordan | Viridian Therapeutics | N/A | |
| Gayle Gironda | Inozyme PharmaInc | N/A | |
| Minji MBA | Mineralys Therapeutics Common | N/A | |
| Trevor Hallam | Sutro Biopharma | 65 | |
| Cindy Berejikian | Mineralys Therapeutics Common | N/A | |
| Venkatesh Srinivasan | Sutro Biopharma | N/A | |
| MBA MD | Replimune Group | 58 | |
| Gregory Perry | Merus BV | 64 | |
| Shan Wu | Viridian Therapeutics | N/A | |
| Danielle Bradbury | Mineralys Therapeutics Common | N/A | |
| Shannon Campbell | Merus BV | N/A | |
| Helen Milton | Viridian Therapeutics | N/A | |
| Brad Fell | Cogent Biosciences | N/A | |
| Timothy Lowinger | Mersana Therapeutics | 60 | |
| MD MBA | Viridian Therapeutics | 59 | |
| Anthony Casciano | Viridian Therapeutics | 47 | |
| Tushar Misra | Mersana Therapeutics | 63 | |
| Chuck Miller | Mersana Therapeutics | N/A | |
| Jan Smith | Revolution Medicines | N/A | |
| Eric Terhaerdt | Cytokinetics | N/A | |
Management Performance
| Return On Equity | -0.41 | ||||
| Return On Asset | -0.26 |
Syndax Pharmaceuticals Leadership Team
Elected by the shareholders, the Syndax Pharmaceuticals' board of directors comprises two types of representatives: Syndax Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Syndax. The board's role is to monitor Syndax Pharmaceuticals' management team and ensure that shareholders' interests are well served. Syndax Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Syndax Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Briggs MD, Head Pres | ||
| Steven Closter, Chief Officer | ||
| Michael MBA, CEO Director | ||
| Steve Sabus, Chief Officer | ||
| Joseph MD, Member Officer | ||
| Ronald Evans, Advisor CoFounder | ||
| Sharon Klahre, Vice Communications | ||
| Peter BSc, CoFounder Officer | ||
| Anjali Ganguli, Chief Officer | ||
| Alexander Nolte, VP Officer | ||
| Neil MD, President Development | ||
| Kevin McManus, Chief Officer | ||
| Michael Downes, CoFounder | ||
| Luke Albrecht, General VP | ||
| Richard Heyman, CoFounder | ||
| Catherine MD, Chief Officer | ||
| Keith CPA, Chief Officer |
Syndax Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Syndax Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.41 | ||||
| Return On Asset | -0.26 | ||||
| Current Valuation | 1.34 B | ||||
| Shares Outstanding | 84.98 M | ||||
| Shares Owned By Insiders | 0.82 % | ||||
| Shares Owned By Institutions | 99.18 % | ||||
| Number Of Shares Shorted | 9.6 M | ||||
| Price To Earning | 126.11 X | ||||
| Price To Book | 3.33 X | ||||
| Price To Sales | 12.67 X |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Syndax Pharmaceuticals in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Syndax Pharmaceuticals' short interest history, or implied volatility extrapolated from Syndax Pharmaceuticals options trading.
Currently Active Assets on Macroaxis
When determining whether Syndax Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Syndax Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Syndax Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Syndax Pharmaceuticals Stock:Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Syndax Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as various price indices. For more information on how to buy Syndax Stock please use our How to Invest in Syndax Pharmaceuticals guide.Note that the Syndax Pharmaceuticals information on this page should be used as a complementary analysis to other Syndax Pharmaceuticals' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Risk-Return Analysis module to view associations between returns expected from investment and the risk you assume.
Complementary Tools for Syndax Stock analysis
When running Syndax Pharmaceuticals' price analysis, check to measure Syndax Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Syndax Pharmaceuticals is operating at the current time. Most of Syndax Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Syndax Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Syndax Pharmaceuticals' price. Additionally, you may evaluate how the addition of Syndax Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon |
Is Syndax Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Syndax Pharmaceuticals. If investors know Syndax will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Syndax Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Syndax Pharmaceuticals is measured differently than its book value, which is the value of Syndax that is recorded on the company's balance sheet. Investors also form their own opinion of Syndax Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Syndax Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Syndax Pharmaceuticals' market value can be influenced by many factors that don't directly affect Syndax Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Syndax Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Syndax Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Syndax Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.